aTyr Pharma
aTyr Pharma
ATYR
NASDAQ
3.61
USD
-9.52%
About
aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs.
Efzofitimod is a tRNA synthetase derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and prevent the progression of fibrosis. ATYR0101 is a fusion protein derived from a domain of aspartyl-tRNA synthetase (DARS).
ATYR0101 binds directly to latent-transforming growth factor beta-binding protein 1 (LTBP1), which regulates transforming growth factor beta (TGFb). Its ATYR0750 is a fusion protein derived from a domain of alanyl-tRNA synthetase (AARS)..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 208.3K |
| Three Month Average Volume | 8.0M |
| High Low | |
| Fifty-Two Week High | 2.5 USD |
| Fifty-Two Week Low | 1.0801 USD |
| Fifty-Two Week High Date | 25 Jul 2024 |
| Fifty-Two Week Low Date | 13 Nov 2023 |
| Price and Volume | |
| Current Price | 1.87 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | -3.27% |
| Thirteen Week Relative Price Change | 0.99% |
| Twenty-Six Week Relative Price Change | -10.96% |
| Fifty-Two Week Relative Price Change | -12.22% |
| Year-to-Date Relative Price Change | 12.00% |
| Price Change | |
| One Day Price Change | -1.06% |
| Thirteen Week Price Change | 8.09% |
| Twenty-Six Week Price Change | -2.09% |
| Five Day Price Change | -1.06% |
| Fifty-Two Week Price Change | 10.00% |
| Year-to-Date Price Change | 32.62% |
| Month-to-Date Price Change | -5.56% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 1.4325 USD |
| Book Value Per Share (Most Recent Quarter) | 1.07668 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 1.4325 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 1.07668 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.96753 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.00659 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.0092 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -0.93998 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.90472 USD |
| Normalized (Last Fiscal Year) | -0.93998 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -0.93998 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.90472 USD |
| Including Extraordinary Items (Last Fiscal Year) | -0.93998 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -0.90472 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 1.55114 USD |
| Cash Per Share (Most Recent Quarter) | 1.03543 USD |
| Cash Flow Per Share (Last Fiscal Year) | -0.92894 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -0.89508 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -1.00243 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -693 |
| Cash Flow Revenue (Trailing Twelve Months) | -10,893 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -9,846.26% |
| Pretax Margin (Last Fiscal Year) | -14,276.77% |
| Pretax Margin (5 Year) | -784.19% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -15,557.79% |
| Operating Margin (Trailing Twelve Months) | -10,633.50% |
| Operating Margin (5 Year) | -806.01% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -14,276.77% |
| Net Profit Margin (Trailing Twelve Months) | -9,846.26% |
| Net Profit Margin (5 Year) | -784.19% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -37.82% |
| Tangible Book Value (5 Year) | 21.92% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -94.34% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -67.68% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 47.98% |
| Total Debt (5 Year) | -34.55% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -0.82% |
| EPS Change (Trailing Twelve Months) | 26.40% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 2 |
| Price to Tangible Book (Most Recent Quarter) | 2 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -76,801,000 |
| Net Debt (Last Fiscal Year) | -96,241,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 402 |
| Price to Sales (Trailing Twelve Months) | 241 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 1 |
| Price to Book (Most Recent Quarter) | 2 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 2 |
| Long Term Debt to Equity (Most Recent Quarter) | 1 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 6 |
| Current Ratio (Most Recent Quarter) | 8 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -37,436,000 |
| Free Cash Flow (Trailing Twelve Months) | -64,049,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 2 |
| Total Debt to Equity (Most Recent Quarter) | 2 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -46.57% |
| Return on Assets (Trailing Twelve Months) | -48.51% |
| Return on Assets (5 Year) | -45.45% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -62.16% |
| Return on Equity (Trailing Twelve Months) | -61.64% |
| Return on Equity (5 Year) | -57.25% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -54.04% |
| Return on Investment (Trailing Twelve Months) | -53.89% |
| Return on Investment (5 Year) | -52.74% |